Joseph Lee, MD
Interventional Cardiology · Colorado Springs, CONPI 1255368460
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $9,716 of the $15,074 with a category attached, or 64.5%. 19 manufacturers reported payments, led by Medtronic at 52.3% of the total. Reporting peaked in 2023 at $5,882 and has fallen 74.1% since, to $1,521 in 2025.
Across 139 payments — averaging $108.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Abbott$2K
- Terumo Medical Corporation$2K
- Philips North America LLC$1K
- Abiomed$363
- Amgen$343
- plus $2K from 13 others
Across 17 payments — averaging $15,273 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$238K
- Amarin Pharma, Inc.$19K
- Abbott$2K
What the payments were for
- Travel & lodging$9,71664%
- Food & beverage$5,35836%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 39 | $7,882 |
| Abbott | 42 | $2,089 |
| Terumo Medical Corporation | 6 | $1,610 |
| Philips North America LLC | 13 | $1,255 |
| Abiomed | 4 | $363 |
| Amgen | 5 | $343 |
| Cardiovascular Systems Inc. | 6 | $221 |
| Boston Scientific | 6 | $188 |
| E.r. Squibb & Sons, L.L.C. | 4 | $165 |
| Heartflow, Inc. | 4 | $161 |
| Chiesi USA, Inc. | 2 | $155 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Penumbra, Inc. | 1 | $122 |
| Pfizer | 1 | $119 |
| AstraZeneca | 1 | $104 |
| Intuitive Surgical | 1 | $79 |
| Edwards Lifesciences | 1 | $35 |
| Johnson & Johnson | 1 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GLIDESHEATH SLENDER$1,459
- Reveal LINQ$1,150
- (6574) Coronary Other$1,014
- OPTIS$761
- Repatha$333
- RESOLUTE ONYX$287
- Resolute$269
- ONYX FRONTIER$149
- KENGREAL 50MG/10ML L$127
- Diamondback Coronary$126
- PRALUENT$125
- Indigo System$122
- Xience Sierra Coronary Stent$120
- VYNDAQEL$119
- Optis Coronary Imaging System$109
- AVVIGO Guidance System$104
- BRILINTA$104
- CAMZYOS$103
- Impella$102
How this compares
$15,074 in reported general payments places this provider in the 65th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 111 | $175,886 |
| XareltoRivaroxaban | 34 | $40,749 |
| Repatha SureclickEvolocumab | 44 | $37,361 |
| Metoprolol Succinate | 224 | $3,489 |
| Atorvastatin Calcium | 315 | $3,263 |
| Losartan Potassium | 131 | $1,583 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 24 | $1,578 |
| Rosuvastatin Calcium | 102 | $1,570 |
| Lisinopril | 165 | $1,262 |
| Nitroglycerin | 38 | $1,258 |
| Flecainide Acetate | 16 | $1,255 |
| ClopidogrelClopidogrel Bisulfate | 90 | $1,184 |
| Chlorthalidone | 49 | $890 |
| Potassium Chloride | 68 | $837 |
| Digoxin | 25 | $671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $119 | $175,886111 claims |
| Johnson & JohnsonXarelto | $33 | $40,74934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Colorado Springs
- Cihan CevikColorado Springs$64K
- Bishal BhandariColorado Springs$12K
- Harshal PatilColorado Springs$9K
- Christopher KovachColorado Springs$8K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.